Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD; Scott Guerin, PhD

Clinical pathways for diabetes could grow by addressing cultural differences, low health literacy of patients and the need for innovative tools and products.
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD and Scott Guerin, PhD discuss how the the upcoming presidential election might impact clinical pathways.
Authors discuss how recent advancements in health care systems have affected physicians' ability to acheive the Triple Aim.
Authors examine different cost control levers the government could use to affect drug pricing and have an impact on treatments selected within clinical pathways. 
Implementing the principles and theories of health psychology can significantly increase patient engagement through the use of targeted messaging, motivational interviewing, and shared decision-making tools. 
A flood of biosimilars is expected to be released in the coming years, Drs. Stefanacci and Guerin discuss how these new drugs will affect the development of new and current clinical pathways.